A peptide fatty acid salt, wherein said peptide fatty acid salt is a salt of a somatostatin type-1, type-2, type-3, type-4 or type-5 analogue or any combination thereof. The peptide fatty acid salt of claim 1, wherein said somatostatin analog is a selective somatostatin receptor type-2.3 agonist. The peptide fatty acid salt of claim 1, wherein said somatostatin analogue is a type 2 somatostatin receptor agonist selected from the group consisting of: D-2-Nal-c (Cys-Tyr-D-Trp-Lys-Val-Cys) -Thr-NH D-Phe-c (Cys-Phe-D-Trp-Lys-Thr-Cys) -Thr-ol [4- (2-hydroxyethyl)] - 1-piperazinylacetyl-D-Phe-c ( Cys-Tyr-D-Trp-Lys-Abu-Cys) -Thr-NH c (Tic-Tyr-D-Trp-Lys-Abu-Phe) 4- (2-hydroxyethyl) -1-piperazin-2- ethanesulfonyl-D-Phe-c (Cys-Tyr-D-Trp-Lys-Abu-Cys) -Thr-NH [4- (2-hydroxyethyl)] - 1-piperazinylacetyl-D-Phe-c (Cys-Tyr -D-Trp-Lys-Abu-Cys) -Thr-NH D-6-propyl-8-β-ergolinylmethylthioacetyl-D-Lys (D-6-propyl-8β-ergolinylmethyl-acetyl) -c (Cys-Tyr-D-Trp-Lys-Abu-Cys) -Thr-NH D-Cpa- (Cys-Tyr-D-Trp-Lys-Val-Cys) -Thr-NH D-Phe-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH D-Phe-Cpa-Tyr -D-Trp-Lys-Thr-Phe-Thr-NH and Ac-c (Cys-Lys-Asn-Cpa-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-D-Cys) -NH. The peptide fatty acid salt of claim 3, wherein said somatostatin type-2 agonist is a dioleate fatty acid salt: D-2-Nal-c (Cys-Tyr-D-Trp-Lys-Val-Cys) -Thr-NH D-Phe-c (Cys-Phe-D-Trp-Lys-Thr-Cys) -Thr-ol or [4- (2-hydroxyethyl)] - 1-piperazinylacetyl-D-Phe-c (Cys-Tyr-D -Trp-Lys-Abu-Cys) -Thr-NH.5. The fatty acid salt of the peptide according to any one of 1-3, wherein said fatty acid is selected from the group consisting of octanoic acid, nonanoic acid, decanoic acid, dodecanoic acid, tetradecanoic acid, cis-9-octadecanoic acid and cis, cis-9,12-octadecanoic acid. The fatty acid salt of the peptide of claim 5, wherein said fatty acid is cis-9-octadecanoic acid. A transdermal delivery composition comprising a fatty acid peptide salt1. Соль жирной кислоты пептида, где указанная соль жирной кислоты пептида является солью аналога ре
